Table 3 Secondary attack rates of household members in individual models
From: Efficacy of baloxavir marboxil on household transmission of influenza infection
n | Secondary attack rates | 95% CI | |
|---|---|---|---|
Age of household patients (years) | |||
0–6 | 47 | 27.5 | 15.9–41.7 |
7–19 | 69 | 13.5 | 6.7–23.5 |
20–64 | 243 | 12.1 | 8.3–16.8 |
≥ 65 | 59 | 12.7 | 6.7–23.5 |
Age of index patients (years) | |||
0–6 | 67 | 18.3 | 10.1–29.3 |
7–19 | 128 | 12.1 | 7.1–18.9 |
20–64 | 167 | 14.5 | 9.6–20.7 |
≥ 65 | 56 | 13.6 | 6.0–25.0 |
Household size | |||
≤ 3 | 116 | 14.8 | 9.0–22.3 |
4 | 163 | 14.9 | 9.9–21.2 |
≥ 5 | 139 | 13.1 | 8.1–19.7 |
Influenza vaccination in the same season in household patients | |||
Yes | 140 | 14.3 | 8.9–21.2 |
No | 278 | 14.2 | 10.5–18.8 |
Index patients with treatment | |||
Baloxavir | 122 | 9.0 | 4.6–15.6 |
Oseltamivir | 296 | 13.5 | 9.8–17.9 |
Respiratory tract symptoms in index patients | |||
Yes | 157 | 15.9 | 10.6–22.6 |
No | 261 | 13.3 | 9.5–17.9 |